The opt-out map just moved twice in two weeks

Six things worth knowing before today's first case.

Let's get into it.

This Week's Top Story

The opt-out map just moved twice in two weeks

Something is shifting, and if you have been in this long enough to feel the ceiling over your head, you are going to feel this one. In the span of eight days, two more states told the federal government they no longer need a physician standing over a CRNA for Medicare to pay the bill. Vermont went first on July 2, the 26th state to opt out. Ohio followed on July 10, the 27th. That is more than half the country now, and the map is moving faster than it has in years.

Step back from the two headlines, because the real story is the shape of the whole map. Twenty-seven states have now opted out, more than half the country. And in the two decades since states got that option, the number has only ever climbed. Each of these wins is the same long argument finally landing, that a CRNA is a full anesthesia provider, not a supervised stand-in, and that the care we give holds up whether or not a rule says a physician has to watch us give it. What used to take years to move from one state to the next is now happening in weeks. That is a profession reaching the tipping point it has been building toward for a generation. The question is not whether the rest of the country follows anymore. It is how fast, and whether your state is out front or falling behind.

And here is why it matters even if your state is not on the list yet. None of this happened by accident. Every state that opted out got there because CRNAs showed up, testified, called their governor, and refused to be called the budget version of anesthesia. The ones still missing are not missing because their CRNAs are less capable, they are missing because the fight has not been won there yet. If that is your state, that is the work, and this is exactly how the map keeps moving.

Our take is at the bottom of this issue ↓

⏱ Act This Week

Pull up your state's current supervision and opt-out status, then read the anesthesia section of your own contract against it. If your state grants more autonomy than your contract does, that gap is a negotiation point, not a fixed rule.

This Month's Number

The share of surgery centers that plan to staff anesthesia through contractors in 2026, in a market where hospital employment used to be the default (VMG Health). The model behind how anesthesia gets covered is being rebuilt right now.

Scope, Moving

Two more bills are worth knowing, for opposite reasons. Rhode Island made a patient-safety move, not a turf grab. Its new law S3184, signed June 18, stops RNs and non-CRNA nurse practitioners from giving general anesthesia and deep sedation for elective cases, and the reason is clinical. Providers without anesthesia training are not prepared to rescue an airway when deep sedation slides into general anesthesia, and propofol, the drug at the center of it, has no reversal agent and a razor-thin margin. Reserving that work for CRNAs and physicians is about who can keep the patient breathing when a case goes sideways. New York is the cautionary tale in the other direction. Its S00357 has stalled in committee, but if it moves forward, it would pull CRNAs back under a physician-collaboration requirement, adding oversight, not removing it. Know where your own state sits.

Drug Shortage Flash

Anesthesia drug shortages shift week to week. See what is short right now before you plan a case around any of it.

Coming to Your OR

Remimazolam, if it has not reached your pharmacy yet, is worth understanding before it does. It is a newer IV anesthetic, an ultra-short-acting benzodiazepine sold as Byfavo, FDA-approved back in 2020. The FDA cleared it only for short procedural sedation, 30 minutes or less, but in practice it is being pushed into general anesthesia and longer cases well past that label. The pitch is that it can be reversed with flumazenil and tends to run more hemodynamically stable than propofol. Here is the honest read, though. Propofol is already fast, cheap, and everywhere, and being reversible matters less for a drug that wears off on its own in minutes, especially since flumazenil fades faster than remimazolam and the patient can slip back under. Whether it is genuinely better than propofol is still an open question, the jury is very much still out.

We will say the quiet part out loud, supervision rules were never really about safety. These fights are about billing, control, and who holds the leverage. Two states opting out in two weeks is not a fluke, it is a country slowly admitting that CRNAs deliver safe anesthesia care and should be paid for the full value of it.

But an opt-out on paper is not autonomy in practice. So celebrate the wins, then keep pushing for the culture to catch up to the law, in the hospitals still writing supervision into contracts the state no longer requires, and in the states that have not moved at all. The law sets the ceiling. Your facility will decide whether you actually get to stand up straight, so do not stop showing up until it does.

If you're thinking it, we're talking about it.

The Anesthesia Brief is free. Built by two CRNAs who wanted one place to find everything.

Read the full brief →

Legislative data, LegiScan & OpenStates (CC BY 4.0). Drug shortage data, ASHP / openFDA. Federal regulatory data, FederalRegister.gov (public domain).